Clinical trials: Age Factor
Wet Macular Degeneration
A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.
This study will evaluate the efficacy, safety, durability, and pharmacokinetics of KSI-301 administered at 12, 16 and 20 weeks intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in…
- Trial name
- DAZZLE (NCT04049266)
- Testing
- KSI-301, Aflibercept
- Where
- 75 sites in United States, Czechia and 5 more
- Volunteers
- 559 people
- Sponsor
- Kodiak Sciences Inc
Macular Degeneration
Complement Factor H Haplotypes and Smoking in Age-related Macular Degeneration
Risk factors for Age-related Macular Degeneration (AMD) involves genetic variations in the alternative pathway of complement inhibitor factor H. The complement system is part of the innate and adaptive immune system.
- Trial name
- CFH&AMD (NCT01115231)
- Where
- 2 sites in United States
- Volunteers
- 223 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Age-Related Macular Degeneration (AMD), Macular Degeneration
X-82 to Treat Age-related Macular Degeneration
The purpose of this study is to evaluate the safety and efficacy of X-82 in the treatment of vision loss due to wet AMD.
- Conditions
- Age-Related Macular Degeneration (AMD), Macular Degeneration, Exudative Age-related Macular Degeneration, AMD
- Trial name
- NCT02348359
- Testing
- X-82, Anti-VEGF
- Where
- 35 sites in United States
- Volunteers
- 157 people
- Sponsor
- Tyrogenex
Acute Coronary Syndrome, Age Problem
Determining the Age of First Acute Coronary Syndrome
The study aimed to evaluate the association between the obesity grade and the age of the first acute coronary syndrome (ACS). The effect of cardiovascular (CV) risk factors and the age of first ACS in patients with severe obesity…
- Conditions
- Acute Coronary Syndrome, Age Problem, Risk Factor, Cardiovascular
- Trial name
- NCT04578964
- Where
- Turkey (Türkiye)
- Volunteers
- 2,000 people
- Sponsor
- Antalya Training and Research Hospital
Neovascular Age-Related Macular Degeneration
Neovascular Morphology and Persistent Disease Activity Among Patients With NV AMD
Neovascular Age-Related Macular Degeneration (NV AMD) remains the leading cause of vision loss among people over 65. Intravitreal injections with drugs that block VEGF have revolutionized treatment of NV AMD.
- Trial name
- NCT02367365
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Duke University
Age-related Macular Degeneration, Choroidal Neovascular Age-related Macular Degeneration
Association of Macular Pigment Optical Density (MPOD) and Genetic Variants in Complement Factor H in Subjects With Choroidal Neovascular (CNV)
Subjects with wet AMD, dry AMD, and age-matched controls will undergo routine occular measurements, will provide a blood and cheek cell sample, and will have macular pigment optical density (MPOD) measured to determine if there…
- Trial name
- NCT01682382
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Sequenom, Inc.
Choroidal Neovascularization
Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
The purpose of study is to determine if Lucentis combined with imatinib mesylate will help treatment in patients with newly diagnosed choroidal neovascularization.
- Trial name
- NCT00403156
- Testing
- Imatinib Mesylate /Ranibizumab
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Vitreous -Retina- Macula Consultants of New York
Atrial Fibrillation
Study of DU-176b Aged 80 Years or Older
The purpose of this study is to evaluate the efficacy and safety of edoxaban in patients with non-valvular NVAF aged 80 years or older who are ineligible for available oral anticoagulation therapy.
- Trial name
- NCT02801669
- Testing
- Du-176b
- Where
- 164 sites in Japan
- Volunteers
- 984 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration
A previous pilot study demonstrated that commonly available glaucoma drops (dorzolamide-timolol) might decrease the amount of chronic swelling in patient with wet age-related macular degeneration who have been receiving…
- Trial name
- DAWN (NCT03034772)
- Testing
- Dorzolamide-timolol, Artificial tears
- Where
- 5 sites in United States
- Volunteers
- 52 people
- Sponsor
- Wills Eye
Neovascular Age Related Macular Degeneration (AMD), Open Angle Glaucoma
TF (SENSIMED Triggerfish) in Intraocular Anti-VEGF (Vascular Endothelial Growth Factor) Injection
This is a prospective, open label study assessing the 24-hour IOP patterns using TF in patients undergoing anti-VEGF injection for the treatment of neovascular AMD (age related macular degeneration).
- Trial name
- NCT01983579
- Testing
- Intraocular anti-VEGF injection, SENSIMED Triggerfish
- Where
- Spain
- Volunteers
- 4 people
- Sponsor
- Sensimed AG
Neovascular Age-Related Macular Degeneration
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
The primary objective of the study is to compare the efficacy of intravitreal (IVT)-administered REGN910-3 compared to intravitreal aflibercept injection (IAI).
- Trial name
- ONYX (NCT02713204)
- Testing
- REGN910-3, Intravitreal Aflibercept Injection (IAI)
- Where
- 87 sites in United States
- Volunteers
- 365 people
- Sponsor
- Regeneron Pharmaceuticals
Renal Function Disorder, Diabetic Macular Edema (DME)
Impact of Intravitreal Faricimab on Renal Function in Diabetic Patients
This study aims to investigate the impact of intravitreal injection of anti-vascular endothelial growth factor (anti VEGF) Faricimab on renal function of diabetic patients.
- Conditions
- Renal Function Disorder, Diabetic Macular Edema (DME), Neovascular Age Related Macular Degeneration
- Trial name
- NCT06929507
- Testing
- Intravitreal injection of Faricimab or Aflibercept 2 mg
- Where
- 2 sites in Greece
- Volunteers
- 60 people
- Sponsor
- University Hospital, Alexandroupolis
Gallstone
The Risk Factors of Symptomatic Gallbladder Stone: Age-Sex Matched Case-control Study Performed in Single Institute
The main purpose of this study is to investigate the region-specific cause of gallbladder stone incidence in Jeju Self-Governing Province, Korea.
- Trial name
- NCT02808546
- Volunteers
- 342 people
- Sponsor
- Cheju Halla General Hospital
Neovacular Age-related Macular Degeneration
UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-vascular Endothelial Growth Factor (VEGF) Effects in Patients With neovascuLar Age-related Macular Degeneration (AMD)
This study assessed systemic vascular endothelial growth factor (VEGF) level in patients with neovascular Age-related Macular Degeneration following treatment with Ranibizumab or Aflibercept.
- Trial name
- UNRAVEL (NCT01988662)
- Testing
- Neovascular Age-related Macular Degeneration
- Where
- 24 sites in Israel, Malaysia and 5 more
- Volunteers
- 205 people
- Sponsor
- Novartis Pharmaceuticals
Dehydration, Glaucoma
Drinking Habits of Glaucoma Patients and Age Matched Controls
The purpose of this study is to examine if a chronic dehydration is a risk factor for the developement or progression of some forms of glaucoma.
- Trial name
- NCT01503996
- Testing
- alter drinking habits
- Where
- Germany
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Technische Universität Dresden
Age Factors
Co-culture and Advanced Maternal Age in PGS Program
Fertilization and embryo development in vivo occurs in appropriate conditions in the mammalian reproductive tract. However in assisted reproductive technology (ART) embryos and oocytes are exposed to certain factors such as…
- Trial name
- CC-PGS (NCT01314846)
- Where
- Spain
- Volunteers
- 346 people
- Sponsor
- IVI Madrid
Macular Degeneration, Geographic Atrophy
GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
Evaluate the effect of IONIS-FB-LRx on the rate of change of the area of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) measured by fundus autofluorescence (FAF).
- Trial name
- NCT03815825
- Testing
- IONIS-FB-LRx
- Where
- 88 sites in United States, Australia and 7 more
- Volunteers
- 332 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Macular Degeneration
Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)
This study examines the effect of intravitreally administered VEGF Trap in patients with wet AMD. The purpose of this trial is to assess the ocular and systemic safety and tolerability of repeated intravitreal doses of VEGF Trap…
- Trial name
- NCT00320788
- Testing
- aflibercept injection (VEGF Trap-Eye, BAY86-5321)
- Where
- 18 sites in United States
- Volunteers
- 159 people
- Sponsor
- Regeneron Pharmaceuticals
Wet Macular Degeneration
OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab
In the Western World, Age Related Macular Degeneration (ARMD) is a leading cause of blindness. This disease was once thought to be a natural part of aging, but recent research has introduced effective treatments.
- Trial name
- STAR (NCT01243086)
- Testing
- Ranibizumab, OZURDEX
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- McMaster University
Fat Mass, Risk Factors Cardiovascular Disease
Follow up Study of Varapodio Trial: Effect of Longevity and Fasting Mimicking Diet on Risk Factors Age Correlated and Biomarkers of Aging
A large ongoing randomized, open-label trial aimed at evaluating the effects of two different dietary interventions, FMD and LD, on body composition and cardiovascular (CV) biomarkers in a real word population (NCT05698654) is…
- Conditions
- Fat Mass, Risk Factors Cardiovascular Disease, Epigenetic Aging, Metabolism Changes
- Trial name
- NCT07255300
- Testing
- fasting mimicking diet
- Where
- Italy
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Fondazione Valter Longo